Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PD-L1 blockade immunotherapy rewires cancer-induced emergency myelopoiesis.
Boumpas A, Papaioannou AS, Bousounis P, Grigoriou M, Bergo V, Papafragkos I, Tasis A, Iskas M, Boon L, Makridakis M, Vlachou A, Gavriilaki E, Hatzioannou A, Mitroulis I, Trompouki E, Verginis P. Boumpas A, et al. Among authors: iskas m. Front Immunol. 2024 Oct 11;15:1386838. doi: 10.3389/fimmu.2024.1386838. eCollection 2024. Front Immunol. 2024. PMID: 39464894 Free PMC article.
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Morris K, Pompilus F, Phillips-Jones A, Zhou XL, Fulci G, Sule N, Kremer BE, Opalinska J, Mateos MV, Trudel S; DREAMM-8 Investigators. Dimopoulos MA, et al. N Engl J Med. 2024 Aug 1;391(5):408-421. doi: 10.1056/NEJMoa2403407. Epub 2024 Jun 2. N Engl J Med. 2024. PMID: 38828951 Clinical Trial.
Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes.
Papalexandri A, Gavriilaki E, Vardi A, Kotsiou N, Demosthenous C, Constantinou N, Touloumenidou T, Zerva P, Kika F, Iskas M, Batsis I, Mallouri D, Yannaki E, Anagnostopoulos A, Sakellari I. Papalexandri A, et al. Among authors: iskas m. Int J Mol Sci. 2023 Nov 7;24(22):16029. doi: 10.3390/ijms242216029. Int J Mol Sci. 2023. PMID: 38003218 Free PMC article.
Adolescents and young adults (AYA) with acute myeloid leukemia (AML): real-world long-term results and age-specific outcomes.
Lalayanni C, Demosthenous C, Iskas M, Kelaidi C, Papathanasiou M, Syrigou A, Athanasiadou A, Papalexandri A, Batsis I, Vardi A, Polychronopoulou S, Sakellari I. Lalayanni C, et al. Among authors: iskas m. Leuk Lymphoma. 2022 Dec;63(13):3128-3137. doi: 10.1080/10428194.2022.2113527. Epub 2022 Aug 24. Leuk Lymphoma. 2022. PMID: 36002396
Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy.
Voso MT, Pandzic T, Falconi G, Denčić-Fekete M, De Bellis E, Scarfo L, Ljungström V, Iskas M, Del Poeta G, Ranghetti P, Laidou S, Cristiano A, Plevova K, Imbergamo S, Engvall M, Zucchetto A, Salvetti C, Mauro FR, Stavroyianni N, Cavelier L, Ghia P, Stamatopoulos K, Fabiani E, Baliakas P. Voso MT, et al. Among authors: iskas m. Br J Haematol. 2022 Jul;198(1):103-113. doi: 10.1111/bjh.18129. Epub 2022 Mar 11. Br J Haematol. 2022. PMID: 35277855
Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML.
Lalayanni C, Gavriilaki E, Athanasiadou A, Iskas M, Papathanasiou M, Marvaki A, Mpesikli S, Papaioannou G, Mallouri D, Batsis I, Papalexandri A, Sakellari I, Anagnostopoulos A. Lalayanni C, et al. Among authors: iskas m. Clin Lymphoma Myeloma Leuk. 2022 Apr;22(4):e233-e240. doi: 10.1016/j.clml.2021.09.019. Epub 2021 Oct 1. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34756570
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities.
Vardi A, Vlachonikola E, Papazoglou D, Psomopoulos F, Kotta K, Ioannou N, Galigalidou C, Gemenetzi K, Pasentsis K, Kotouza M, Koravou E, Scarfó L, Iskas M, Stavroyianni N, Ghia P, Anagnostopoulos A, Kouvatsi A, Ramsay AG, Stamatopoulos K, Chatzidimitriou A. Vardi A, et al. Among authors: iskas m. Clin Cancer Res. 2020 Sep 15;26(18):4958-4969. doi: 10.1158/1078-0432.CCR-19-3827. Epub 2020 Jul 2. Clin Cancer Res. 2020. PMID: 32616500
Brentuximab vedotin and anti-PD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data.
Sakellari I, Gavriilaki E, Iskas M, Bousiou Z, Chatziioannidis A, Batsis I, Mallouri D, Constantinous V, Stavroyianni N, Syrigou A, Marvaki A, Pilavaki M, Papaemmanouel S, Anagnostopoulos A. Sakellari I, et al. Among authors: iskas m. Hematol Oncol. 2019 Oct;37(4):490-492. doi: 10.1002/hon.2645. Epub 2019 Jul 24. Hematol Oncol. 2019. PMID: 31339579 Clinical Trial. No abstract available.
22 results